PDS in mid-stage PDS0101/Keytruda combo trial in head & neck cancer

• PDS Biotechnology (NASDAQ:PDSB) has initiated VERSATILE-002 Phase 2 trial evaluating the combination of its lead candidate, PDS0101 and Merck's Keytruda (pembrolizumab) for the first-line treatment of head and neck cancer that has returned or spread.
• The 100-subject study will evaluate the efficacy and safety of PDS0101/pembrolizumab combo, with main efficacy endpoint as shrinkage of the tumor referred to as the objective response rate at nine months following the initiation of treatment.
• In separate partnership with the National Cancer Institute, and The University of Texas MD Anderson Cancer Center, PDS Biotech is conducting additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer respectively.
• PDS0101 is an immunotherapy designed to treat HPV-related cancers.
• https://seekingalpha.com/news/3634223-pds-biotech-launches-mid-stage-pds0101-combo-trial-in-head-neck-cancer